Skip to main content
. 2023 May 8;14(8):1321–1334. doi: 10.7150/jca.84632

Figure 3.

Figure 3

The therapeutic potential of macrophage-targeted T-EVs: (A) Using modified T-EVs as vaccines that stimulate macrophages to clear T-EVs; (B) T-EVs with native and loaded cargos polarize macrophages toward an anti-tumor M1 phenotype; (C) T-EVs can target macrophages via integrins and their ligands on the membrane; (D) The blood circulation time of T-EVs is likely to be longer than that of non-tumor-cell-derived EVs due to the higher amount of “don't eat me” signal CD47 and the lower level of “eat me” signal PS.